Clinical Trial Search

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03 — 3; 3; 2; 0 Participants

Primary: Response Rate as Measured Per RECIST 1.1 Criteria — 12; 2 Participants

Primary: Maximum Tolerated Dose (MTD) of LMB-100 With Tofacitinib — 100 mcg/kg given days 4, 6, 8 every cycle

Primary: 1-year Progression-free Survival — 44; 33 percentage of participants

Primary: Ability of PD-L1 to Predict Response — 0.377 Youden index

Primary: Change in Ratio of Intratumoral Cytotoxic T Cells to Regulatory T Cells (CD8/Treg) — 8.6 no unit of ratios with same units(%) — p=0.109

Primary: Objective Response (OR) (Partial Responses + Complete Responses) in Phase 2 Subjects of Short Infusion LMB-100+ Nab-paclitaxel — 1 Participants

Primary: Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression — 6.7; 6.8; 5.26 months

Primary: Recommended Phase 2 Dose (RP2D) of LMB100 + Nab-paclitaxel — 140; 100 mcg

Primary: Response Assessment — 0; 0; 0; 0 Participants

Primary: Objective Response (Partial and Complete) Per RECIST — 1 participants

Primary: Percentage of Patients That Had at Least One Additional Lesion Detected Under Pegsitacianine Guidance Following CRS That Was Confirmed as Positive for Disease by…

Primary: Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST) — 47.8 percentage of…

Primary: Major Pathologic (Disease) Response of Tumor to Nivolumab Combined With Ipilimumab Before Surgery

Primary: Pre-treatment OSCC Morphology and PDPN Expression — 2.8; 3.4; 2.5 score on a scale from 1 to 5 — p=<0.05

Primary: Phase 1: Maximum Tolerated Dose of PEN-221 and Recommended Phase 2a Dose (RP2D) — 18.0 mg

Primary: 3-month Progression Free Survival Rate — 3 Participants

Primary: Best Response — 0; 7; 11; 11 participants

Primary: Progression-free Survival (PFS), [95% CI] — 4.3; 4.5 months — p=0.859125

Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001

Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants

Primary: Overview of Adverse Events — 28; 23; 12; 1 participants

Primary: Progression Free Survival (PFS) as Assessed by Independent Radiological Review — 2.5; 3.4 months — p=0.76

Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants

Primary: Pathological Complete Response — 3 participants

Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants

Primary: To Determine the Sensitivity High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles to Identify Small and Otherwise Undetectable…

Primary: Best Overall Response by RECIST Criteria (Version 1.0) — 3; 0; 7; 6 eligible, treated participants

Primary: Number of Participants With Progression Free Survival (PFS) Responders and Non-responders at Month 6 — 26; 51 Participants

Primary: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) During Cycle 1, Per Common Terminology Criteria for Adverse Events (AEs), Version 5.0 (CTCAE) — 2…